99 related articles for article (PubMed ID: 22222457)
1. Structure-based drug design on membrane protein targets: human integral membrane protein 5-lipoxygenase-activating protein.
Ferguson AD
Methods Mol Biol; 2012; 841():267-90. PubMed ID: 22222457
[TBL] [Abstract][Full Text] [Related]
2. 4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP).
Banoglu E; Çelikoğlu E; Völker S; Olgaç A; Gerstmeier J; Garscha U; Çalışkan B; Schubert US; Carotti A; Macchiarulo A; Werz O
Eur J Med Chem; 2016 May; 113():1-10. PubMed ID: 26922224
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein.
Ferguson AD; McKeever BM; Xu S; Wisniewski D; Miller DK; Yamin TT; Spencer RH; Chu L; Ujjainwalla F; Cunningham BR; Evans JF; Becker JW
Science; 2007 Jul; 317(5837):510-2. PubMed ID: 17600184
[TBL] [Abstract][Full Text] [Related]
4. Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis.
Gür ZT; Çalışkan B; Banoglu E
Eur J Med Chem; 2018 Jun; 153():34-48. PubMed ID: 28784429
[TBL] [Abstract][Full Text] [Related]
5. A Single Amino Acid Difference between Mouse and Human 5-Lipoxygenase Activating Protein (FLAP) Explains the Speciation and Differential Pharmacology of Novel FLAP Inhibitors.
Blevitt JM; Hack MD; Herman K; Chang L; Keith JM; Mirzadegan T; Rao NL; Lebsack AD; Milla ME
J Biol Chem; 2016 Jun; 291(24):12724-12731. PubMed ID: 27129215
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7.
Levent S; Gerstmeier J; Olgaç A; Nikels F; Garscha U; Carotti A; Macchiarulo A; Werz O; Banoglu E; Çalışkan B
Eur J Med Chem; 2016 Oct; 122():510-519. PubMed ID: 27423639
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of endo- and exo-aryl-substitutions and central scaffold modifications on diphenyl substituted alkanes as 5-lipoxygenase activating protein inhibitors.
Chu L; Armstrong HM; Chang LL; Cheng AF; Colwell L; Cui J; Evans J; Galka A; Goulet MT; Hayes N; Lo J; Menke J; Ok HO; Ondeyka DL; Patel M; Quaker GM; Sings H; Witkin SL; Zhao A; Ujjainwalla F
Bioorg Med Chem Lett; 2012 Jun; 22(12):4133-8. PubMed ID: 22578458
[TBL] [Abstract][Full Text] [Related]
8. Structure-based, multi-targeted drug discovery approach to eicosanoid inhibition: Dual inhibitors of mPGES-1 and 5-lipoxygenase activating protein (FLAP).
Ho JD; Lee MR; Rauch CT; Aznavour K; Park JS; Luz JG; Antonysamy S; Condon B; Maletic M; Zhang A; Hickey MJ; Hughes NE; Chandrasekhar S; Sloan AV; Gooding K; Harvey A; Yu XP; Kahl SD; Norman BH
Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129800. PubMed ID: 33246032
[TBL] [Abstract][Full Text] [Related]
9. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases.
Evans JF; Ferguson AD; Mosley RT; Hutchinson JH
Trends Pharmacol Sci; 2008 Feb; 29(2):72-8. PubMed ID: 18187210
[TBL] [Abstract][Full Text] [Related]
10. Ligand-based Modeling for the Prediction of Pharmacophore Features for Multi-targeted Inhibition of the Arachidonic Acid Cascade.
Saroj Devi N; Shanmugam R; Ghorai J; Ramanan M; Anbarasan P; Doble M
Mol Inform; 2018 Mar; 37(3):. PubMed ID: 28991413
[TBL] [Abstract][Full Text] [Related]
11. Recent advances for FLAP inhibitors.
Pettersen D; Davidsson Ö; Whatling C
Bioorg Med Chem Lett; 2015 Jul; 25(13):2607-12. PubMed ID: 26004579
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP).
Banoglu E; Çalişkan B; Luderer S; Eren G; Özkan Y; Altenhofen W; Weinigel C; Barz D; Gerstmeier J; Pergola C; Werz O
Bioorg Med Chem; 2012 Jun; 20(12):3728-41. PubMed ID: 22607880
[TBL] [Abstract][Full Text] [Related]
13. Discovery and optimization of oxadiazole-based FLAP inhibitors.
Bartolozzi A; Abeywardane A; Bosanac T; Broadwater JA; Chen Z; Hutzler JM; Huber JD; Nemoto P; Olague A; Riether D; Simpson T; Takahashi H; Wu L; Zhang Y; Zindell RM
Bioorg Med Chem Lett; 2017 Oct; 27(20):4652-4659. PubMed ID: 28927794
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase.
Garscha U; Romp E; Pace S; Rossi A; Temml V; Schuster D; König S; Gerstmeier J; Liening S; Werner M; Atze H; Wittmann S; Weinigel C; Rummler S; Scriba GK; Sautebin L; Werz O
Sci Rep; 2017 Aug; 7(1):9398. PubMed ID: 28839250
[TBL] [Abstract][Full Text] [Related]
15. Discovery of the first dual inhibitor of the 5-lipoxygenase-activating protein and soluble epoxide hydrolase using pharmacophore-based virtual screening.
Temml V; Garscha U; Romp E; Schubert G; Gerstmeier J; Kutil Z; Matuszczak B; Waltenberger B; Stuppner H; Werz O; Schuster D
Sci Rep; 2017 Feb; 7():42751. PubMed ID: 28218273
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis.
Ago H; Kanaoka Y; Irikura D; Lam BK; Shimamura T; Austen KF; Miyano M
Nature; 2007 Aug; 448(7153):609-12. PubMed ID: 17632548
[TBL] [Abstract][Full Text] [Related]
17. The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP).
Pergola C; Gerstmeier J; Mönch B; Çalışkan B; Luderer S; Weinigel C; Barz D; Maczewsky J; Pace S; Rossi A; Sautebin L; Banoglu E; Werz O
Br J Pharmacol; 2014 Jun; 171(12):3051-64. PubMed ID: 24641614
[TBL] [Abstract][Full Text] [Related]
18. Targeting 5-lipoxygenase-activating protein in asthma and chronic obstructive pulmonary disease.
Antoniu SA
Expert Opin Ther Targets; 2014 Nov; 18(11):1285-92. PubMed ID: 25213852
[TBL] [Abstract][Full Text] [Related]
19. Structure-based discovery of inhibitors of microsomal prostaglandin E2 synthase-1, 5-lipoxygenase and 5-lipoxygenase-activating protein: promising hits for the development of new anti-inflammatory agents.
De Simone R; Chini MG; Bruno I; Riccio R; Mueller D; Werz O; Bifulco G
J Med Chem; 2011 Mar; 54(6):1565-75. PubMed ID: 21323313
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological cross-reactivity between 5-lipoxygenase-activating protein, 5-lipoxygenase, and leukotriene C4 synthase.
Gupta N; Nicholson DW; Ford-Hutchinson AW
Can J Physiol Pharmacol; 1997; 75(10-11):1212-9. PubMed ID: 9431445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
